Investigation into Aardvark Therapeutics Securities Class Action Amid Safety Claims#USA#New_York#Bryan_Jones#AARD_stock#Aardvark_Inc
Investigation into Aardvark Therapeutics Securities Class Action Amid Safety Claims
Aardvark Therapeutics faces a class action lawsuit over misleading safety claims regarding its drug ARD-101, with major implications for investors.
third-news.com
September 3, 2026 at 2:45 PM
Investigation into Aardvark Therapeutics Securities Class Action Amid Safety Claims#USA#New_York#Bryan_Jones#AARD_stock#Aardvark_Inc
Aardvark Therapeutics Faces Legal Challenges Over IPO Misstatements#USA#San_Francisco#class_action_lawsuit#Aardvark_Therapeutics#AARD_stock
Aardvark Therapeutics Faces Legal Challenges Over IPO Misstatements
Investors in Aardvark Therapeutics are alerted about a pending class action lawsuit concerning misleading statements made during its IPO process.
third-news.com
August 20, 2026 at 1:58 PM
Aardvark Therapeutics Faces Legal Challenges Over IPO Misstatements#USA#San_Francisco#class_action_lawsuit#Aardvark_Therapeutics#AARD_stock